3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - 3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta.

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Coronavirus Disease 2019 (COVID-19), Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Skin Cancer, Solid Tumor and Unspecified Cancer.

The latest report 3 Phosphoinositide Dependent Protein Kinase 1 - Drugs In Development, 2022, outlays comprehensive information on the 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)
• The report reviews 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope